Form 4: Verastem Director Eric K. Rowinsky Receives New Equity Compensation Awards

Verastem, Inc. Director Eric K. Rowinsky was granted 8,333 Restricted Stock Units and options to purchase 12,500 shares of common stock, vesting over approximately one year.

Summary

• Verastem, Inc. (VSTM) Director Eric K. Rowinsky was granted 8,333 Restricted Stock Units (RSUs) on May 22, 2025, under the Issuer's Amended and Restated 2021 Equity Incentive Plan.
• Each RSU represents the contingent right to receive one share of Common Stock, granted at a price of $0.00.
• Following this transaction, Mr. Rowinsky beneficially owns 16,666 shares of Common Stock.
• Additionally, Mr. Rowinsky was granted stock options to purchase 12,500 shares of Common Stock with an exercise price of $7.48 per share, also on May 22, 2025.
• The stock options have an expiration date of May 22, 2035.
• Both the RSUs and stock options vest in twelve equal installments, with the first eleven installments vesting beginning on the last day of each month from June 2025 to April 2026.
• The final installment for both awards will vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026.
• Vesting for both awards is contingent upon Mr. Rowinsky's continued service as a director of Verastem, Inc. on each respective vesting date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a standard compensation practice that aligns director interests with the company's long-term performance and continued service, without indicating any negative operational or financial news.

Positives

• The grants of RSUs and stock options align the director's interests with long-term shareholder value through equity-based compensation.
• The structured vesting schedule encourages continued service and commitment from a key director over the next year.

Negatives

• The future issuance of new shares upon vesting of RSUs and exercise of options will result in a minor dilutive effect for existing shareholders.

Risks

• Vesting of the equity awards is contingent on the reporting person's continued service as a director; if service ceases before vesting dates, unvested awards will be forfeited.
• The intrinsic value of the stock options is dependent on the future market price of Verastem's common stock exceeding the exercise price of $7.48 per share.

Future Outlook

The vesting schedule for the granted RSUs and stock options extends through May 2026, contingent on the director's continued service, indicating an expectation of ongoing commitment from the director to the company's long-term performance.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across industries, particularly in the biotechnology and pharmaceutical sectors, to incentivize long-term commitment and align executive interests with shareholder value. Such grants are standard components of director compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs and exercise of options, but also benefit from incentivized director commitment and alignment of interests.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership within the company.

Next Steps

• Continued service of Eric K. Rowinsky as a director of Verastem, Inc. for the equity awards to vest.
• Monthly vesting of RSUs and stock options from June 2025 to April 2026, with the final installment vesting by May 31, 2026 or the day before the 2026 Annual Meeting of Stockholders.

Key Dates

Keywords

Verastem, VSTM, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership